Get answers to your Multiple myeloma questions.
A recently published multi-institutional Phase I study initiated and chaired by Dr. Ashraf Badros at the University of Maryland Greenebaum Cancer Center evaluated a new combination of drugs -- bortezomib and vorinostat -- for the treatment of relapsed or refractory multiple myeloma patients. The study was sponsored and funded by National Cancer Institute (NCI). The trial established in a Phase I design the appropriate doses of each drug.
According to Dr. Badros, "The regimen was well-tolerated by the study participants and had promising anti-myeloma activity in relapsed and refractory multiple myeloma patients. This work is the basis of ongoing national and international Phase II and III clinical trials to confirm the overall response of patients."
The study, entitled "Phase I Study of Vorinostat in Combination with Bortezomib for Relapsed and Refractory Multiple Myeloma," was published in the August 15, 2009, issue of Clinical Cancer Research, a journal of the American Association for Cancer Research (AACR).